指南与共识皮肤肿瘤银屑病与炎症性皮肤病

实体器官移植受者皮肤鳞状细胞癌预防的共识建议:Delphi共识声明

Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement.
指南 / 共识 · JAMA Dermatol · 2021-01-01

该Delphi共识针对实体器官移植受者皮肤鳞状细胞癌(CSCC)的预防,由48名皮肤科医生通过三轮网络调查形成建议。共识基于光化性损伤与皮肤癌指数(AD-SCI)的6个阶段,对其中5个阶段给出了推荐,包括冷冻治疗、局部场治疗、联合治疗以及阿维A和免疫抑制调整等。对于首次低危CSCC患者未达成共识。

要点

  • 散在光化性角化病推荐冷冻治疗,同一解剖区域群集时推荐场治疗。
  • 场癌化皮肤推荐氟尿嘧啶联合病灶导向与场治疗。
  • 每年发生10个CSCC或高危CSCC(淋巴结转移风险约≥20%)时启动阿维A并讨论免疫抑制调整。

核心结论

  • 医生可考虑实施专家组建议以预防实体器官移植受者皮肤鳞状细胞癌,同时等待高级别证据。
  • 在未达成共识的领域需要进一步临床试验。

研究设计与样本

  • 研究为Delphi共识过程,邀请有超过5年治疗实体器官移植受者经验的皮肤科医生参与。

主要发现

  • 当呈现关于预防实体器官移植受者CSCC的陈述、问题或管理策略时,受访者达到80%或更高的一致性即视为共识,并定义了70%至不足80%的一致性为近共识类别。
  • 专家组能够为6个AD-SCI阶段中的5个提出建议。
  • 对于首次低风险CSCC的实体器官移植受者未达成共识建议。

关键数值与推荐

  • 散在光化性角化病(AK)推荐冷冻治疗。
  • AK在同一解剖区域群集时推荐场治疗,除非AK较厚则推荐场治疗联合冷冻治疗。
  • 场癌化皮肤推荐氟尿嘧啶联合病灶导向治疗与场治疗。
  • 对于以高频率(每年10个CSCC)发生多个皮肤癌或发生高危CSCC(定义为肿瘤淋巴结转移风险约≥20%)的患者,推荐启动阿维A治疗并讨论减少或调整免疫抑制。

临床怎么用

  • 临床医生可参考专家组建议对实体器官移植受者进行CSCC预防,包括根据AD-SCI阶段选择冷冻治疗、场治疗、联合治疗及系统治疗。
  • 对于发生多个皮肤癌或高危CSCC的患者,应考虑启动阿维A并评估免疫抑制方案调整。

局限性

  • 证据基础薄弱,缺乏高级别证据指导实体器官移植受者CSCC预防。
  • 对于首次低风险CSCC患者未达成共识建议。
  • 共识基于Delphi过程,可能存在专家意见偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a paucity of evidence to guide physicians regarding prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTRs). OBJECTIVE: To examine the development and results of a Delphi process initiated to identify consensus-based medical management recommendations for prevention of CSCC in SOTRs. EVIDENCE REVIEW: Dermatologists with more than 5 years' experience treating SOTRs were invited to participate. A novel actinic damage and skin cancer index (AD-SCI), consisting of 6 ordinal stages corresponding to an increasing burden of actinic damage and CSCC, was used to guide survey design. Three sequential web-based surveys were administered from January 1, 2019, to December 31, 2020. Pursuant to Delphi principles, respondents thoroughly reviewed all peer responses between rounds. Supplemental questions were also asked to better understand panelists' rationale for their responses. FINDINGS: The Delphi panel comprised 48 dermatologists. Respondents represented 13 countries, with 27 (56%) from the US. Twenty-nine respondents (60%) were Mohs surgeons. Consensus was reached with 80% or higher concordance among respondents when presented with a statement, question, or management strategy pertaining to prevention of CSCC in SOTRs. A near-consensus category of 70% to less than 80% concordance was also defined. The AD-SCI stage-based recommendations were established if consensus or near-consensus was achieved. The panel was able to make recommendations for 5 of 6 AD-SCI stages. Key recommendations include the following: cryotherapy for scattered actinic keratosis (AK); field therapy for AK when grouped in 1 anatomical area, unless AKs are thick in which case field therapy and cryotherapy were recommended; combination lesion directed and field therapy with fluorouracil for field cancerized skin; and initiation of acitretin therapy and discussion of immunosuppression reduction or modification for patients who develop multiple skin cancers at a high rate (10 CSCCs per year) or develop high-risk CSCC (defined by a tumor with approximately ≥20% risk of nodal metastasis). No consensus recommendation was achieved for SOTRs with a first low risk CSCC. CONCLUSIONS AND RELEVANCE: Physicians may consider implementation of panel recommendations for prevention of CSCC in SOTRs while awaiting high-level-of-evidence data. Additional clinical trials are needed in areas where consensus was not reached.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Massey PR, Schmults CD, Li SJ, et al. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement. JAMA Dermatol. 2021. PMID: 34468690. doi:10.1001/jamadermatol.2021.3180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。